Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

Active
Yes
Status
Posted
Published Date
December 14th, 2023
Close Date
November 15th, 2024
Award Ceiling
$300,000.00
Opportunity No.
RFA-CA-24-017

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) has posted a grant opportunity titled "Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)". This grant aims to advance cancer model systems that replicate human immunity in the tumor microenvironment to enhance the predictability of immuno-oncology studies. The proposed research projects should focus on recreating the human immune system in cancer models using human cells or tissues, either in vivo or in vitro. The goal is to achieve a level of representation of the human immune system that surpasses what can be achieved with murine models. Models that do not involve the introduction of human immune lineage cells will not be considered responsive. The funding instrument for this opportunity is a Cooperative Agreement, and there is no cost sharing or matching requirement. The grant has a maximum award ceiling of $300,000. Eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for applications is November 15, 2024. For more information and to apply, visit the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-017.html. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Description

The goal of this FOA is to advance cancer model systems that recapitulate human immunity in the tumor microenvironment to improve the predictivity of immuno-oncology studies. Proposed research projects must focus on recapitulation of the human immune system in their proposed cancer model using human cells or tissues to regenerate and/or recapitulate the human immune system in in vivo or in vitro immuno-oncology models in a manner that matches or exceeds representation of the human immune system achieved with murine models developed using HFT. Models derived from genetically manipulated immune systems without introduction of human immune lineage cells will not be considered responsive.The FOA will utilize the R33 Exploratory/Developmental Grants Phase II research activity code.

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)". This grant aims to support the development and enhancement of emerging informatics technologies that improve the acquisition, management, analysis, and dissemination of data and knowledge in cancer research. The grant focuses on informatics technology that has passed the initial prototyping and pilot development stage, has the potential for significant impact, and has not been widely adopted in the cancer research field. The goal is to address priority needs in cancer research across the entire cancer research continuum, including cancer biology, treatment and diagnosis, early detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. Applicants must provide a clear rationale for the proposed technology and demonstrate how it will benefit the cancer research field. The development plans should include mechanisms to solicit feedback from users and collaborators throughout the process. The grant does not require cost sharing or matching. The maximum award ceiling for this grant is $600,000. The opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments, non-domestic entities, regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The closing date for applications is November 15, 2024. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-018.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-018.html). Any inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)". This opportunity falls under the category of Health and is a Cooperative Agreement. The grant does not require cost sharing or matching. The purpose of this grant is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. The aim is to incentivize independent validation and accelerate the suitability of emerging technologies for cancer research. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The close date for this grant is October 1, 2024, and the award ceiling is $150,000. For more information and to apply, please visit the following link: [Grant Information](http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-013.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)". This grant aims to provide continued development and sustainment of high-value informatics research resources for improving the acquisition, analysis, visualization, and interpretation of data in cancer research. The grant focuses on sustaining operations and enhancing the user experience and availability of existing informatics tools and resources that are widely adopted. It aims to support the fields of cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. Applicants eligible for this grant include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The grant opportunity does not require cost sharing or matching. It falls under the category of Cooperative Agreement and is classified as discretionary funding. The CFDA number associated with this grant is 93.399. The deadline for submitting applications is November 15, 2024. The grant description emphasizes the need for a sustainment plan that justifies the maintenance of the research resource and demonstrates its benefits to the cancer research field. The plan should also include mechanisms for assessing and maximizing the value of the resource to researchers and promoting collaboration with the targeted research community. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-019.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-019.html). Any inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)". This grant is in the category of Health and falls under the funding instrument type of Grant. The grant does not require any cost sharing or matching requirement. The opportunity is discretionary and falls under CFDA number 93.394. The purpose of this grant is to encourage revision applications from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. The aim is to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. This grant aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The grant has a closing date of October 1, 2024, and the award ceiling is $150,000. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-012.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-012.html). For any inquiries, the grantor can be contacted at grantsinfo@nih.gov.